LSE:AZN (AstraZeneca PLC)

About AZN

AstraZeneca is a biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Respiratory, Inflammation and Autoimmunity (RIA), Cardiovascular and Metabolic Disease (CVMD) and Oncology – as well as in Infection and Neuroscience.
  • AstraZeneca PLC (LSE: AZN) Latest News

    Investing Articles

    These 2 bargain dividend stocks could beat the FTSE 100 in 2017

    Improving financial performance could allow these two stocks to outperform the FTSE 100 (INDEXFTSE:UKX).

    Read more »

    Investing Articles

    Now Neil Woodford owns just eight FTSE stocks!

    Renowned blue-chip master Neil Woodford now owns just eight FTSE 100 (INDEXFTSE: UKX) stocks.

    Read more »

    Investing Articles

    2 dependable shares to retire on

    Bilaal Mohamed reveals two perfect picks for long-term income investors.

    Read more »

    Investing Articles

    Will this spin-off stock continue to slay FTSE 100 giants?

    Roland Head asks if this potential FTSE 100 (INDEXFTSE:UKX) giant killer is worth the risk.

    Read more »

    Investing Articles

    3 FTSE 100 stocks I’d never sell

    There are some FTSE 100 (INDEXFTSE:UKX) shares that really do deserve to be held forever.

    Read more »

    Investing Articles

    Is this the FTSE 100’s top growth stock?

    This FTSE 100 (INDEXFTSE: UKX) unsung hero good could be a top growth pick, says G A Chester.

    Read more »

    Investing Articles

    3 great income stocks I’d buy today

    If you are looking for a base rate busting income these three FTSE 100 companies are a great place to…

    Read more »

    Investing Articles

    A FTSE 100 giant with 20% upside to consider

    This blue chip could have a possible upside of 20%.

    Read more »

    Investing Articles

    Are shares in GlaxoSmithKline plc now in bargain territory?

    Paul Summers casts his eyes over today's results from pharmaceutical giant GlaxoSmithKline plc (LON:GSK).

    Read more »

    Investing Articles

    Should you buy or sell AstraZeneca plc after FY sales fall 5%?

    Roland Head reviews 2016 results from AstraZeneca plc (LON:AZN) and asks whether the firm's ambitious goals deserve a buy rating.

    Read more »

    Investing Articles

    After revenue jumps 60%, is Oxford Biodynamics plc a buy?

    Could Oxford Biodynamics PLC (LON: OBD) be London's next super growth stock?

    Read more »

    Investing Articles

    2 hot FTSE 100 dividend stocks I’d buy in February

    These two shares offer excellent income potential.

    Read more »